We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biotech firm ANA Therapeutics has begun Phase II/III trial to analyse the safety and efficacy of its oral niclosamide (ANA001) formulation for treating patients with moderate Covid-19.